CAS: 1146699-66-2; (R)-2-((4-Chloro-N-(2-Fluoro-4-(1,2,4-Oxadiazol-3-yl)Benzyl)Phenyl)Sulfonamido)-5,5,5-Trifluoropentanamide

该化合物是一个复杂的有机化合物,其多功能结构包括五氯化萘脊柱,一个磺酰组和一个三氟甲基组;4-氯苯基的存在有助于其潜在的生物活动,而1,2,4-oxadiazole环则可能加强其药理特性;该化合物可能由于氨基和磺基功能而呈现极性特征,这可能影响其溶性和再活动;已知三氟甲基组具有独特的电子特性,有可能影响该化合物与生物目标的相互作用;此外,(2R)所显示的立体化学化学学表明可能对生物功效至关重要的具体空间安排;

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号1146699-70-8 (R)-2-(4-chloro... | CAS号122-51-0 原甲酸三乙酯 | CAS号1146699-64-0 3-[4-(溴甲基)-3-氟苯... | CAS号1146699-67-3 Pentanamide, 2-...

合成工艺路线路线简述

  • 合成目标产物 Avagacestat (Bms-708163) 主要起始原料 1,2,4-Oxadiazole, 3-[4-(Bromomethyl)-3-Fluorophenyl]- And Pentanamide, 2-[[(4-Chlorophenyl)Sulfonyl]Amino]-5,5,5-Trifluoro-, (2R)-
  • (文献来源)合成步骤主要原料 1,2,4-Oxadiazole, 3-[4-(Bromomethyl)-3-Fluorophenyl]- 和 Pentanamide, 2-[[(4-Chlorophenyl)Sulfonyl]Amino]-5,5,5-Trifluoro-, (2R)-
(R)-2-(4-Chloro-N-(2-Fluoro-4-(N'-Hydroxycarbamimidoyl)Benzyl)Phenylsulfonamido)-5,5,5-Trifluoropentanamide 以 甲醇,水,乙腈 用作溶剂,化学反应 4.0H,反应生成γ-Secretase抑制剂(Bms-708163)
参考文献:Novel Alpha-(N-Sulfonamido)Acetamide Compound As An Inhibitor Of Beta Amyloid Peptide Production
标题:Novel Alpha-(N-Sulfonamido)Acetamide Compound As An Inhibitor Of Beta Amyloid Peptide Production
摘要:本发明提供了一种新型的α-(N-磺胺基)乙酰胺化合物,其药物组合物,其制备方法以及用于治疗阿尔茨海默病和其他与β-淀粉样肽相关疾病的方法.

海关参考信息

专利信息


专利号:US-10682335-B2
优先权日:2014-07-28
标题 :Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same
发明人:SU HONG-LIN; CHANG CHIA-YU; HWANG SHIAW-MIN; Lu huai-en; HARN HORNG-JYH; LIN SHINN-ZONG; LAI PING-SHAN
权利人:EVERFRONT BIOTECH INC
摘要:The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the β-amyloid protein (Aβ) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of Aβ in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered. Furthermore, the method for preparing a pharmaceutical composition containing Bdph comprises preparing the pharmaceutical composition through an organic synthesis reaction, wherein the Bdph is coated with a polymeric material such as F127 by covalent bonding of the polymeric material with the Bdph, thereby achieving the effect of reducing the cytotoxicity of the pharmaceutical composition for an organism.

专利号:US-9771379-B2
优先权日:2015-09-24
标题:N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides
发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS
权利人:PFIZER
摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nwherein the variables R 1 , R 2 , R 3 , R 4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-8962616-B2
优先权日:2012-05-04
标 题:Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; BECK ELIZABETH MARY; DAVOREN JENNIFER ELIZABETH; O'NEILL BRIAN THOMAS
权利人:PFIZER
摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9744173-B2
优先权日:2014-04-10
标题 :2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
发明人:BRODNEY MICHAEL AARON; BECK ELIZABETH MARY; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS; BARREIRO GABRIELA; LACHAPELLE ERIK ALPHIE; ROGERS BRUCE NELSEN
权利人:PFIZER
摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nand the variable R 1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9751895-B2
优先权日:2015-09-24
标 题:N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides
发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS; VERHOEST PATRICK ROBERT; MIKOCHIK PETER JUSTIN; MURRAY JOHN CHARLES; HOU XINJUN
权利人:PFIZER
摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nand the variables R 1 , R 2 and R 3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9260455-B2
优先权日:2012-09-20
标 题 :Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
发明人:BRODNEY MICHAEL AARON; BECK ELIZABETH MARY; BUTLER CHRISTOPHER RYAN; DAVOREN JENNIFER ELIZABETH
权利人:PFIZER
摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, n nwherein the variables R 1 and R 2 are as defined in the specification.n n Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
上海泽涵生物医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.zehanbiopharma.com
电话: 021-61350663 13052117465👤
📞上海泽涵生物医药科技有限公司 ⚠️参考联系方式

销售电话:021-61350663 13052117465
邮箱:sales@zehanbiopharma.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
上海兴默生物技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.xmobio.com
电话: 0086 13524779951; 13524779951👤
📞上海兴默生物技术有限公司 ⚠️参考联系方式

销售电话:0086 13524779951; 13524779951
邮箱:sales@xmobio.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y. Structural basis of γ-secretase inhibition and modulation by small molecule drugs. Cell. 2021 Jan 21;184(2):521-533.e14. doi: 10.1016/j.cell.2020.11.049. Epub 2020 Dec 28. 163(2):525-542. doi: 10.1093/toxsci/kfy048. 72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607. 344(3):686-95. doi: 10.1124/jpet.112.199356. Epub 2012 Dec 28. 32(11):761-9. doi: 10.1007/s40261-012-0006-4. 91(12):1316-1324. doi: 10.1136/jnnp-2020-323497. Epub 2020 Oct 12. 69(11):1430-40. doi: 10.1001/archneurol.2012.2194. 75(1):136-45. doi: 10.1111/j.1365-2125.2012.04339.x.
9: Sivaraman L, Sanderson T. Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats. Toxicol Appl Pharmacol. 2023 Jun 15;469:116512. doi: 10.1016/j.taap.2023.116512. Epub 2023 Apr 6. 51(10):681-93. doi: 10.1007/s40262-012-0005-x. 34(3):654-67. doi: 10.1016/j.clinthera.2012.01.022. Epub 2012 Feb 28. 55(6):5047-5058. doi: 10.1007/s12035-017-0705-1. Epub 2017 Aug 16.
13: Simutis FJ, Sanderson TP, Pilcher GD, Graziano MJ. Investigations on the Relationship Between Ovarian, Endocrine, and Renal Findings in Nonclinical Safety Studies of the γ-Secretase Inhibitor Avagacestat. Toxicol Sci. 2019 Sep 1;171(1):98-116. doi: 10.1093/toxsci/kfz129. 57(10):600-5. doi: 10.1002/jlcr.3224. Epub 2014 Sep 5. 13(4):514. doi: 10.3390/pharmaceutics13040514.

合成参考文献


参考文献:10.1124/jpet.112.199356
摘要:Albright CF, Dockens RC, Meredith JE, Olson RE, Slemmon R, Lentz KA, Wang J, Denton RR, Pilcher G, Rhyne PW, Raybon JJ, Barten DM, Burton C, Toyn JH, Sankaranarayanan S, Polson C, Guss V, White R, Simutis F, Sanderson T, Gillman KW, Starrett JE, Bronson J, Sverdlov O, Huang S, Castaneda L, Feldman H, Coric V, Zaczek R, Macor JE, Houston J, Berman RM, Tong G. Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat. The Journal of Pharmacology and Experimental Therapeutics. 2013 Mar;344(3):686–95. doi: 10.1124/jpet.112.199356.
参考文献:10.1007/s00228-012-1459-3
摘要:Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SAG. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD A model-based meta-analysis of γ-secretase inhibitor data. European Journal of Clinical Pharmacology. 2013 Jan 04;69(6):1247–60. doi: 10.1007/s00228-012-1459-3.
参考文献:10.1007/s12035-019-01677-8
摘要:Lopez-Font I, Boix CP, Zetterberg H, Blennow K, Sáez-Valero J. Characterization of Cerebrospinal Fluid BACE1 Species. Mol Neurobiol. 2019 Dec;56(12):8603–16. doi: 10.1007/s12035-019-01677-8.
摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知